Human Immunodeficiency Virus Type 1 Latency Model for High-Throughput Screening

Sofiya Micheva-Viteva, Annmarie L. Pacchia, Yacov Ron, Stuart W. Peltz, and Joseph P. Dougherty*

Department of Molecular Genetics, Microbiology and Immunology, UMDNJ-Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, New Jersey 08854

Received 8 June 2005/Returned for modification 26 August 2005/Accepted 29 September 2005

Human immunodeficiency virus type 1 (HIV-1) is not eliminated from patients even after years of antiretroviral therapy, apparently due to the presence of latently infected cells. Here we describe the development of a cell-based system of latency that can be used for high-throughput screening aimed at novel drug discovery to eradicate HIV-1 infection.

Highly active antiretroviral therapy (HAART) has led to a significant improvement in the care and survival of patients infected with human immunodeficiency virus type 1 (HIV-1). However, even after long-term suppression of viral replication with HAART, the virus rapidly rebounds after therapy is discontinued (2, 3). A key contributor to viral rebound appears to be a reservoir of latently infected cells, including CD4+ memory T cells. The half-life of the latently infected population is quite long, and it is estimated that it would take over 60 years of HAART to eliminate this population (4). Therefore, lifelong HAART would be required to control infection in patients.

A potentially fruitful approach to eliminating virus infection would be to identify small compounds with pharmacological properties that allow these molecules to access latently infected cell reservoirs in order to activate latent proviruses and to use them in conjunction with HAART to flush out the virus. There is precedent for small molecule activation of latent HIV-1. For example, valproic acid (VPA) was found to be able to activate latent virus in a model cell culture system (18). Subsequently, a clinical study was performed in which four patients were treated with VPA for 4 to 6 weeks, and three of the four patients demonstrated a significant decrease in the number of latently infected T cells (8). Although latent virus was not totally cleared from any of the patients, the evidence indicates that an approach using pharmacological agents might ultimately be developed that would result in clearance of the virus from infected individuals. Here a cell-based assay is described that can be utilized in high-throughput screening (HTS) to discover novel compounds capable of activating latent HIV-1.

To develop an HIV-1 latency model for HTS, the secretable alkaline phosphatase (seap) gene, encoding a truncated form of placental alkaline phosphatase, was used (1). It provides a very sensitive chemiluminescent assay when used in conjunction with the alkaline phosphatase substrate CSPD [disodium 4-chloro-3-[(methoxy)spiro[1,2-dioxetane-3,2’-(5’-chloro)tricyclo(3.3.1.1{3,7})decan]-4’-yl]phenyl phosphate] and as such is amenable to HTS. Since a hallmark of active replication is production of the HIV-1 late proteins including the viral envelope polyprotein (Env), the seap gene was inserted in the env position to serve as an indicator of late gene expression (Fig. 1). Disruption of the env gene by insertion of seap also adds a level of safety to the system by preventing production of the essential Env polyprotein. In order to impart an additional level of safety, 2.5 kb of the pol gene was also deleted (Fig. 1). The enhanced green fluorescent protein (egfp) reporter gene was inserted 5’ to the nef start codon such that it should be expressed from the multiply spliced nef mRNA (Fig. 1) (13, 15). The egfp gene was included in the system to provide an early gene expression marker that would allow single-cell analysis of viral infection by flow cytometry, as has been previously reported (5, 7).

Next, human T-cell clones derived from SupT1 cells and harboring latent vector provirus were isolated, NLE-7-S-G vector virus (Fig. 1) was propagated and used to inoculate SupT1 cells as previously described (10–12). A mass population of infected SupT1 cells was maintained for 1 month, by which time most SEAP and GFP expression became extinguished (data not shown). Cell clones were then isolated by limiting dilution according to the standard procedures. Clones were tested to determine if they harbored latent virus that could be stimulated with tumor necrosis factor alpha (TNF-α). Flow cytometry to monitor GFP expression showed that after treatment with TNF-α there was a significant increase in the number of cells expressing GFP within each of three clonal populations (Fig. 1B); however, a relatively small fraction of the cells were not activated. This varied expression indicates that there might be some level of epigenetic regulation of expression (16) and disparate responses of cells to TNF-α stimulation in different phases of the cell cycle (14). All three lines also exhibited a significant induction in SEAP activity after treatment with TNF-α. By day 2 posttreatment, SEAP activity increased by approximately 50-, 400-, and 150-fold in lines 19ST1NLESG, 24ST1NLESG, and 29ST1NLESG, respectively (Fig. 1C).

* Corresponding author. Mailing address: Department of Molecular Genetics, Microbiology and Immunology, UMDNJ-Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854. Phone: (732) 235-4588. Fax: (732) 235-5223. E-mail: doughejp@umdnj.edu.
stable over time. The variation in the induction of the three cell clones was primarily due to differences between the background levels of expression (Fig. 1C). Since the proviruses are integrated in different positions in the genome (data not shown), the local site of integration can influence expression from the provirus and may account for the different levels of background expression (6, 9, 17). It was also found that induction of vector virus mRNA levels paralleled those of seap, egfp, and gag gene expression after TNF-α/H9251 treatment (data not shown). It is also noteworthy that Southern blotting confirmed that each cell clone harbored a single NLE-S-G provirus (data not shown), and standard assays demonstrated that the cell lines were devoid of replication-competent virus (data not shown).

For the assay to be useful in an HTS it must be reliable in a small-well format. Assay optimization and validation require the determination of the Z factor (Z'), a dimensionless statistical characteristic used to assess the quality of data generated in a potential HTS assay (19). The Z' values for the current latency assay were calculated based on the analysis of SEAP expression from uninduced (negative) and induced (positive) 24ST1NLESG cells in a 96-well format using the equation:

\[
Z' = 1 - \frac{(3\sigma_{positive} + 3\sigma_{negative})}{|\mu_{positive} - \mu_{negative}|}
\]

where \(\sigma\) represents the standard deviation and \(\mu\) is the mean of each set of data points.

\(Z'\) is a commonly used measure of assay performance and reliability that takes into account both the assay signal dynamic range (signal-to-background ratio) and variation (signal-to-noise ratio) associated with the measured signals. A perfect assay would have a \(Z'\) value of 1, while an excellent assay would score between 0.5 and 1 (19). Using three different activators, \(Z'\) values ranging between 0.55 and 0.8 were obtained, indicating excellent assay reliability (Fig. 2).

In summary, we have developed a safe and reliable assay of HIV-1 latency that should be amenable to HTS. Moreover, this
is the first HIV-1 latency model that has been developed with the idea to utilize it for HTS to identify novel small molecules that can be employed to eradicate latent virus from infected individuals.

REFERENCES


